Cedars-Sinai's venture capital strategy focuses on investing in early-stage healthcare and biomedical science startups, including those developed by their own clinicians and staff, to improve healthcare delivery, efficiency, and patient outcomes. They provide capital, clinical validation, access to data, and mentorship, often acting as the first funder, customer, and pilot site for new companies.
80% of their portfolio is in Healthcare. They made 1 investments in the last 12 months. Their most common stage is series-e (40% of deals). Average disclosed round size is $73.0M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
$275M
Top Stage
Series E
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Visby Medical | Growth | $55M | Jun 2025 |
| Visby Medical | Series E | $35M | Jun 2022 |
| Visby Medical | Series E | $135M | Jun 2022 |
| VVirti | Series A | $10M | Jun 2021 |
 Prometheus Biosciences | Growth | $130M | Nov 2020 |
Top Co-Investors
ND Capital3 shared
Blue Water Life Science Advisors3 shared
J2 ventures2 shared
Perceptive Advisors1 shared
Cormorant Asset Management1 shared
Point72 Ventures1 shared
Ascend Venture Capital1 shared
IQ Capital1 shared
Lightrock1 shared
Catalio Capital Management1 shared
Last updated: 16 April 2026